May 2020 CBPP Spotlight

Patients With AL Amyloidosis May Benefit From Subcutaneous Daratumumab/CyBorD Combination

August 20, 2020

Clinical Articles

Adding a subcutaneous formulation of daratumumab to the triplet regimen cyclophosphamide, bortezomib, and dexamethasone may hold promise for patients with newly diagnosed light chain amyloidosis who are in urgent need of new treatment options, according to a clinical trial.

Gerber Addresses the Role of Mutations and Treatment in NSCLC at Different Stages

May 23, 2020

In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.